Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Journal of Thoracic Oncology · 2025-11 · 20 (11) · 1655-1668
DOI: 10.1016/j.jtho.2025.06.030 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thoracic Oncology, 2025-11. Verfasst von Se-Hoon Lee und 33 weiteren Autor:innen. Beteiligte Einrichtung: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: sehoon.lee119@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson Pharmaceutical Research and Development LLC.
Abstract (Originalsprache)
INTRODUCTION: Lazertinib is a central nervous system-penetrant, third-generation EGFR tyrosine kinase inhibitor (TKI) that was selected for combination with amivantamab due to its relatively low rates of wild-type EGFR toxicities. In the phase 3 MARIPOSA study, amivantamab plus lazertinib (amivantamab-lazertinib) significantly improved progression-free survival (PFS; p < 0.001) versus osimertinib in participants with treatment-naive EGFR-mutant advanced NSCLC. A lazertinib monotherapy arm was included to assess the contribution of components in the combination. This is the first randomized, double-blind comparison of two third-generation EGFR TKIs, lazertinib and osimertinib. METHODS: In MARIPOSA, 1074 participants were randomized 2:2:1 to receive amivantamab-lazertinib (n = 429), osimertinib monotherapy (n = 429), or lazertinib monotherapy (n = 216). This exploratory analysis compared the efficacy and safety of lazertinib and osimertinib. RESULTS: At a median follow-up of 22.0 months, median PFS was 18.5 months for lazertinib versus 16.6 months for osimertinib (hazard ratio = 0.98, 95% confidence interval: 0.79-1.22; p = 0.86). PFS results were comparable between arms among predefined subgroups. Among participants with measurable disease at baseline, objective response rate was 83% for lazertinib versus 85% for osimertinib, with a median duration of response among confirmed responders of 16.6 months versus 16.8 months, respectively. Median overall survival was not reached for both arms (hazard ratio = 1.00, 95% confidence interval: 0.73-1.38) at the interim analysis. Adverse events for both arms were mostly grades 1 to 2 and frequently related to EGFR inhibition. Lazertinib was associated with lower rates of QT interval prolongation versus osimertinib. CONCLUSIONS: Lazertinib demonstrated comparable efficacy and safety to osimertinib, including in predefined subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: sehoon.lee119@gmail.com.
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
- Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Virginia Cancer Specialists, Fairfax, Virginia.
- Institut du Thorax Curie-Montsouris, Paris, France; Paris-Saclay University, UVSQ, Versailles, France.
Förderung
- Johnson and Johnson Pharmaceutical Research and Development LLC
Zitieren
APA
Lee, S. H., Lu, S., Hayashi, H., Felip, E., Spira, A. I., Girard, N., Kim, Y. J., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Dias, J. M., Lee, K. H., Xiong, H., How, S. H., Cheng, Y., Chang, G. C., Chih-Hsin Yang, J., …, & Cho, B. C. (2025). Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA. Journal of Thoracic Oncology, 20(11), 1655-1668. https://doi.org/10.1016/j.jtho.2025.06.030
Vancouver
Lee SH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, et al. Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA. Journal of Thoracic Oncology. 2025;20(11):1655-1668. doi:10.1016/j.jtho.2025.06.030
BibTeX
@article{Lee2025,
author = {Lee, Se-Hoon and Lu, Shun and Hayashi, Hidetoshi and Felip, Enriqueta and Spira, Alexander I and Girard, Nicolas and Kim, Yu Jung and Ostapenko, Yurii and Danchaivijitr, Pongwut and Liu, Baogang and Alip, Adlinda and Korbenfeld, Ernesto and Dias, Josiane Mourão and Lee, Ki Hyeong and Xiong, Hailin and How, Soon Hin and Cheng, Ying and Chang, Gee-Chen and Chih-Hsin Yang, James and Besse, Benjamin and Thomas, Michael and Shah, Sujay and Baig, Mahadi and Curtin, Joshua C and Zhang, Jiarui and Xie, John and Sun, Tao and Sethi, Seema and Wang, Miao and Fennema, Elizabeth and Daksh, Mahesh and Ennis, Mariah and Bauml, Joshua M and Cho, Byoung Chul},
title = {Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA},
journal = {Journal of Thoracic Oncology},
year = {2025},
volume = {20},
number = {11},
pages = {1655--1668},
doi = {10.1016/j.jtho.2025.06.030}
}
EUVIMED